The Leiden Bio Science Park TechTalk podcast is where we talk about what the organizations in Leiden do to beat COVID-19, from vaccines to food, we discuss all the different initiatives right here in this podcast. My name is Joep van den Eerenbeemt, and with me is Hans Tanke, now retired but a renowned scientist in the field of molecular cell biology at the Leiden University Medical Centre. Together we will interview scientists, entrepreneurs and innovators. We won’t stop asking questions until we have found out what COVID-19 is exactly, what it does to our bodies and what our guests are doing to battle this pandemic.
Joep van den Eerenbeemt
Business Developer LSH
Retired but a renowned scientist in the
field of molecular cell biology
Leinden University Medical Centre
Episode 1: Now live
Why is COVID-19 so harmful to some patients and nearly harmless to others?
Professor of Respiratory Cell Biology and Immunology
and head of the research laboratory of the Department of Pulmonology at the Leiden University Medical Center.
Click here to listen op Spotify
Episode 2: Now live
We have heard about,vaccines to prevent coronavirus and medicines options to cure the disease, but in this episode we learn about a completely different approach.
Eric van der Veer
Chief Scientific Officer at Hybridize Therapeutics
A RNA-based therapeutics company that focuses on
developing small molecules that specifically target viruses,
including SARS-CoV-2, the virus responsible for the current COVID-19 pandemic.
Click here to listen on Spotify
TechTalks organized by
- Joep van den Eerenbeemt (InnovationQuarter)
- Maria Plug (Hogeschool Leiden)
- Kim Habets (Boerhaave Nascholing & LUMC)
- Roisin Holmes (Luris)
- Esmé Postma (Stichting LBSP)
- Hans Tanke (LUMC)
Participants to our events can be recorded on photo and/or video. The Leiden Bio Science Park organisation has the right to use these captured images for promotion purposes through its own website, social media or other publication channels. In case you do not approve your picture to be published, we kindly request you to inform us by e-mail: email@example.com.